Immunohistochemistry in the diagnosis of dysplasia in chronic inflammatory bowel disease colorectal polyps

Brahim, Ehsen Ben; Mrabet, Ali; Jouini, Raja; Koubaa, Wafa; Sidhom, Rimel B.; Elloumi, Héla; Chadli, A

doi:10.1016/j.ajg.2016.06.003

Cited by 5 publications

(6 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent study has also reported that p53 immunostaining showed nuclear staining in the basal part of the crypts, even in the indefinite for dysplasia lesions [49]. Wild-type p53 protein in normal cells has a very short half-life [50], and there is no such amount as to be positive by immunostaining.…”

Section: Histopathological Diagnosis Of Ucmentioning

confidence: 99%

“…Immunostaining of p53 is useful as a tissue biomarker for predicting the risk of renewal changes, differentiation of intraepithelial neoplasms, and the evolution to malignant tumors, including colorectal cancers [49,63,64]. In UC-associated dysplasia, overexpression of p53 protein in the colonic epithelium is also found and detected in cases where the dysplasia is otherwise histologically difficult to determine (Figure 3).…”

Section: P53 Expression As a Diagnostic Marker In Uc-associated Dymentioning

confidence: 99%

See 1 more Smart Citation

p53 Expression as a Diagnostic Biomarker in Ulcerative Colitis-Associated Cancer

Kobayashi

Tomita

Shimizu

et al. 2017

IJMS

View full text Add to dashboard Cite

Ulcerative colitis (UC) is defined as an idiopathic inflammatory disorder primarily involving the mucosa and submucosa of the colon. UC-associated colon cancers (also known as colitic cancers) develop through the inflammation–dysplasia sequence, which is a major problem affecting the prognosis of patients with UC. It is therefore very important to detect malignancy from UC at an early stage. As precancerous lesions arising in UC, there are pathological adenomatous changes, basal cell changes, in situ anaplasia, clear cell changes, and pan-cellular change. It is considered that the mutation of the p53 gene plays a crucial role, and the protein expression of p53 in dysplastic crypts may serve as a good biomarker in the early stages of UC-associated colon carcinogenesis. Immunohistochemistry for p53 is a very valuable diagnostic tool in UC-associated colon cancers. However, protein expression of p53 is not always universal, and additional methods may be required to assess p53 status in UC-associated colon cancers.

show abstract

Section: Histopathological Diagnosis Of Ucmentioning

confidence: 99%

Section: P53 Expression As a Diagnostic Marker In Uc-associated Dymentioning

confidence: 99%

p53 Expression as a Diagnostic Biomarker in Ulcerative Colitis-Associated Cancer

Kobayashi

Tomita

Shimizu

et al. 2017

IJMS

View full text Add to dashboard Cite

show abstract

“…Some evidence suggests biomarkers of AMACR, Ki-67, and p53 can be useful in detecting neoplastic epithelium, though may not be sensitive in the indefinite for dysplasia category. 8,9 Recent studies have shown that the special AT-rich sequence-binding protein 2 (SATB2) biomarker is lost in some IBD-associated adenocarcinomas and dysplasias, 10,11 but preserved with high sensitivity and specificity in benign colonic mucosa and in sporadic adenocarcinomas. We investigated the prevalence of loss of SATB2 expression in biopsies otherwise interpreted as indefinite for dysplasia.…”

mentioning

confidence: 99%

“…In such cases, pathologists currently have limited additional diagnostic tools to aid in the important treatment altering distinction between a precancerous lesion versus inflamed but benign tissue. Some evidence suggests biomarkers of AMACR, Ki-67, and p53 can be useful in detecting neoplastic epithelium, though may not be sensitive in the indefinite for dysplasia category 8,9. Recent studies have shown that the special AT-rich sequence-binding protein 2 (SATB2) biomarker is lost in some IBD-associated adenocarcinomas and dysplasias,10,11 but preserved with high sensitivity and specificity in benign colonic mucosa and in sporadic adenocarcinomas.…”

mentioning

confidence: 99%

Association Between Loss of SATB2 Expression in Inflammatory Bowel Disease Indefinite for Dysplasia and a Diagnosis of Definitive Dysplasia on Follow-up

Cretara¹,

Knee

Mueller³

et al. 2022

American Journal of Surgical Pathology

View full text Add to dashboard Cite

Special AT-rich sequence-binding protein 2 (SATB2) is a sensitive and specific biomarker for sporadic colonic adenocarcinomas. Previous studies have found that SATB2 is lost in some adenocarcinomas and dysplasias associated with inflammatory bowel disease (IBD). In establishing these findings, the prior studies did not examine cases of IBD interpreted as indefinite for dysplasia. We examined SATB2 expression in this diagnostic category to determine if any potential loss is associated with a diagnosis of definitive dysplasia on follow-up. To investigate this possibility, we collected 87 biopsies of IBD indefinite for dysplasia from 62 patients and stained them with SATB2. Among patients’ indefinite for dysplasia, we found SATB2 loss in 6/62 (9.7%). Among those with follow-up (n=51), we observed 5/6 (83%) with a future dysplasia in those with SATB2 loss compared with 10/45 (22%) in those with SATB2 retention, absolute difference 61.1% (95% confidence interval=28.9%-93.3%). We conclude that loss of SATB2 on biopsies otherwise interpreted as IBD indefinite for dysplasia may mark a population at high risk for showing definitive dysplasia on future biopsies.

show abstract

“…17,18 Many studies have identified Alpha-methylacyl-CoA racemase (AMACR) as a valuable biomarker in the detection of epithelial dysplastic changes across a range of conditions such as chronic inflammatory bowel disease and colorectal polyps. 19 AMACR is a peroxisomal and mitochondrial enzyme with an important role in regulating the metabolism of lipids and drugs. Neither NF-κB-p65 nor AMACR have previously been assessed for their ability to distinguish oral lichenoid and dysplastic lesions.…”

Section: Introductionmentioning

confidence: 99%

Immunoexpression of oral brush biopsy enhances the accuracy of diagnosis for oral lichen planus and lichenoid lesions

Idrees

Shearston

Farah

et al. 2022

J Oral Pathology Medicine

View full text Add to dashboard Cite

Background: This study assessed the efficacy of using oral liquid-based brush cytology (OLBC) coupled with immunostained cytology-derived cell-blocks, quantified using machine-learning, in the diagnosis of oral lichen planus (OLP).Methods: Eighty-two patients diagnosed clinically with either OLP or oral lichenoid lesion (OLL) were included. OLBC samples were obtained from all patients before undergoing surgical biopsy. Liquid-based cytology slides and cell-blocks were prepared and assessed by cytomorphology and immunocytochemistry for four antibodies (Ki-67, BAX, NF-κB-p65, and AMACR). For comparison purposes, a sub-group of 31 matched surgical biopsy samples were selected randomly and assessed by immunohistochemistry. Patients were categorized according to their definitive diagnoses into OLP, OLL, and clinically lichenoid, but histopathologically dysplastic lesions (OEDL). Machine-learning was utilized to provide automated quantification of positively stained protein expression.Results: Cytomorphological assessment was associated with an accuracy of 77.27% in the distinction between OLP/OLL and OEDL. A strong concordance of 92.5% (κ = 0.84) of immunostaining patterns was evident between cell-blocks and tissue sections using machine-learning. A diagnostic index using a Ki-67-based model was 100% accurate in detecting lichenoid cases with epithelial dysplasia. A BAX-based model demonstrated an accuracy of 92.16%. The accuracy of cytomorphological assessment was greatly improved when it was combined with BAX immunoreactivity (95%).Conclusions: Cell-blocks prepared from OLBC are reliable and minimally-invasive alternatives to surgical biopsies to diagnose OLLs with epithelial dysplasia when combined with Ki-67 immunostaining. Machine-learning has a promising role in the automated quantification of immunostained protein expression.

show abstract

Immunohistochemistry in the diagnosis of dysplasia in chronic inflammatory bowel disease colorectal polyps

Cited by 5 publications

References 10 publications

p53 Expression as a Diagnostic Biomarker in Ulcerative Colitis-Associated Cancer

p53 Expression as a Diagnostic Biomarker in Ulcerative Colitis-Associated Cancer

Association Between Loss of SATB2 Expression in Inflammatory Bowel Disease Indefinite for Dysplasia and a Diagnosis of Definitive Dysplasia on Follow-up

Immunoexpression of oral brush biopsy enhances the accuracy of diagnosis for oral lichen planus and lichenoid lesions

Contact Info

Product

Resources

About